Pacira BioSciences, Inc.
PCRX
$23.00
-$0.18-0.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.24% | 5.00% | 5.14% | 6.49% | 1.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.24% | 5.00% | 5.14% | 6.49% | 1.73% |
| Cost of Revenue | 8.07% | 6.14% | 14.82% | -11.80% | -7.67% |
| Gross Profit | 5.71% | 4.71% | 2.52% | 11.97% | 4.84% |
| SG&A Expenses | 3.65% | 8.26% | 27.63% | 23.49% | 30.02% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.98% | 7.23% | 26.29% | 13.46% | 16.95% |
| Operating Income | 29.87% | -40.90% | -107.82% | -40.08% | -70.51% |
| Income Before Tax | 232.59% | -42.59% | -97.76% | 106.86% | -105.27% |
| Income Tax Expenses | -171.85% | -46.53% | -111.24% | -11.24% | -83.50% |
| Earnings from Continuing Operations | 196.00% | -39.40% | -89.79% | 103.79% | -125.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 196.00% | -39.40% | -89.79% | 103.79% | -125.66% |
| EBIT | 29.87% | -40.90% | -107.82% | -40.08% | -70.51% |
| EBITDA | -7.70% | -10.48% | -51.68% | -31.65% | -26.48% |
| EPS Basic | 210.60% | -30.67% | -88.92% | 103.96% | -126.06% |
| Normalized Basic EPS | 1,002.81% | -69.94% | -114.46% | -19.90% | -104.13% |
| EPS Diluted | 207.18% | -30.00% | -88.38% | 103.86% | -128.29% |
| Normalized Diluted EPS | 984.27% | -70.05% | -115.17% | -20.65% | -104.53% |
| Average Basic Shares Outstanding | -13.19% | -12.56% | -7.97% | -4.54% | -1.55% |
| Average Diluted Shares Outstanding | -11.35% | -12.07% | -12.35% | -3.63% | -10.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |